Research & products
We run to, not from, the world’s biggest health challenges.
The journey to invention and discovery is guided by science – and inspired by patients
Our purpose is to save and improve lives for generations. Our strategy is simple: We follow the science. The path to discovery is often unclear, but we are tireless in seeking solutions for some of the world’s most difficult health challenges.
Our work in numbers
people employed in research and development
people reached through our major programs and partnerships
invested in R&D in 2019
We address the world’s most difficult health challenges, following world-class science
Discovery & development
Our progress is due in large part to the important and tough scientific questions we set out to answer with our trials and collaborations. We are grateful to the thousands of volunteers who participate in our clinical trials – making this all possible.
Our commitment to patients is unwavering
As long as there are still patients in hospitals, doctors and nurses desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here, fighting with all we have to deliver more, sooner.
Invention begins here
Our scientists are applying the latest groundbreaking research technologies and revolutionizing how we discover and develop medicines and vaccinesView our stories
Our new London Discovery Research Center site
The $1.32 billion, 220,000-square-foot research facility will be located in London’s “Knowledge Quarter”Read more
Next: Our new London Discovery Research Center site
2Q 2020 Financial results
Merck announced second-quarter worldwide sales of $10.9 billion – a decrease of 8% compared with the second quarter of 2019 – reflecting the negative impact of COVID-19. Excluding the impact from foreign exchange, sales declined 5%. The company anticipates full-year 2020 revenue range to be between $47.2 billion and $48.7 billion, including a negative […]Read more
Next: 2Q 2020 Financial results
Lessons from dual pandemics
A conversation with Merck Chief Patient Officer Julie Gerberding, M.D., M.P.H., about her early work caring for people with HIV and AIDS, and the parallels of the AIDS and COVID-19 pandemicsRead more
Next: Lessons from dual pandemics
No patient left behind in our clinical trials
We’re here for patients when they need us mostRead more
Next: No patient left behind in our clinical trials
If you build it (in 3D), they will come
Innovating with the power of 3D printingRead more
Next: If you build it (in 3D), they will come